Aseptuva raises CHF 2.4 M

Aseptuva is developing far-UVC light disinfection technology at the catheter entry point to prevent hospital-acquired infections. The Swiss-British medtech raised CHF 2.4 million in seed funding last year from healthcare entrepreneurs and investors, which enabled it to reach preclinical validation.

Announced on
Round
Seed
Amount
CHF 2.4 M
Location
Bern
Sector
Health & medtech

Investors

  • Simon Michel
  • Roger Nitsch
  • Armin Diethelm
  • Auxinam
  • weInvest
  • Valuemaker
  • Fortyone

Preparing a similar round?

The diagnostic shows you the instruments and investors that fit your stage.

Start the diagnostic